Current and future management of serious skin and skin-structure infections.
The purpose of this study was to compare in a randomized, open-label clinical study, the efficacy and safety of cefepime (1 g every 12 hours) with that of ceftazidime (1 g every 8 hours) in patients with serious skin and skin-structure infections. Of 298 patients enrolled in the study, 130 with serious skin and skin-structure infections were evaluable. Demographics and underlying medical conditions were comparable in both groups. The most common infections were cellulitis, abscesses, ulcers, and postoperative wound infections. The most common pathogens isolated were Staphylococcus aureus, group A streptococci, Enterobacteriaceae, and Pseudomonas aeruginosa. Duration of therapy in the 93 patients treated with cefepime was 3-18 days and in the 37 ceftazidime-treated patients was 4-16 days. Pathogen bacteriologic response rates were high: 92% (124 of 135) of pathogens were eradicated by cefepime and 95% (55 of 58) by ceftazidime. Clinical response rates were satisfactory in 88% (82 of 93) of cefepime-treated patients and in 89% (33 of 37) of ceftazidime-treated patients. Adverse events occurred with similar frequency in both groups. Events probably related to study drugs affected 3% (6 of 198) of patients treated with cefepime and 4% (4 of 100) of ceftazidime-treated patients. Cefepime, a new parenteral cephalosporin administered every 12 hours, is an extremely well tolerated and effective alternative to ceftazidime given every 8 hours for the treatment of serious skin and skin-structure infections.
Schwartz
R
R
Associates in Infectious Diseases and Research, Fort Myers, Florida 33901, USA.
Das-Young
L R
LR
Ramirez-Ronda
C
C
Frank
E
E
D001419:Bacteria / Q000187:drug effects / Q000302:isolation & purification; D000077723:Cefepime; D002442:Ceftazidime / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D002511:Cephalosporins / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008826:Microbial Sensitivity Tests / Q000706:statistics & numerical data; D008875:Middle Aged; D012871:Skin Diseases / Q000188:drug therapy* / Q000382:microbiology; D017192:Skin Diseases, Bacterial / Q000188:drug therapy* / Q000382:microbiology
D002511:Cephalosporins; D000077723:Cefepime; D002442:Ceftazidime